b'<style type="text/css">\r\n\t\t\t.cs2E86D3A6{text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0pt}\r\n\t\t\t.cs5925EB86{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:bold;font-style:normal;}\r\n\t\t\t.cs95E872D0{text-align:left;text-indent:0pt;margin:0pt 0pt 0pt 0pt}\r\n\t\t\t.csDD5E5F52{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:normal;font-style:normal;}\r\n\t\t\t.csED7826F6{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:14pt;font-weight:bold;font-style:italic;}\r\n\t\t\t.csE0B838BE{text-align:justify;text-indent:-86pt;margin:0pt 0pt 0pt 86pt}\r\n\t\t\t.csA16174BA{color:#000000;background-color:transparent;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;}\r\n\t\t\t.cs9224F58F{text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:12pt;mso-line-height-rule:exactly}\r\n\t\t\t.csC970676{text-align:left;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:12pt;mso-line-height-rule:exactly}\r\n\t\t\t.cs5ADD8C59{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:9pt;font-weight:normal;font-style:normal;}\r\n\t\t\t.csE2DB38B2{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:9pt;font-weight:bold;font-style:italic;}\r\n\t\t\t.cs5D3E032C{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:9pt;font-weight:normal;font-style:normal;text-decoration: line-through;}\r\n\t\t\t.cs41ED3027{text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:12pt;mso-line-height-rule:exactly}\r\n\t\t\t.csE3E0FE0B{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:normal;font-style:italic;}\r\n\t\t\t.cs5CA3ADAD{text-align:left;text-indent:0pt;margin:0pt 0pt 0pt 54pt;line-height:12pt;mso-line-height-rule:exactly}\r\n\t\t\t.csD15247B9{text-align:left;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:1.5}\r\n\t\t\t.csF0A1D375{text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:1.5}\r\n\t\t\t.cs22FF6315{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:bold;font-style:italic;}\r\n\t\t\t.cs98AF35F2{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:normal;font-style:normal;text-decoration: line-through;}\r\n\t\t</style>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\r\n\r\n\t\t<p class="cs2E86D3A6"><span class="cs5925EB86">SB 450 - VERSION ADOPTED BY BOTH BODIES</span></p><p class="cs2E86D3A6"><span class="cs5925EB86">&nbsp;</span></p><p class="cs95E872D0"><span class="csDD5E5F52">03/31/2022 &nbsp;&nbsp;1202s</span></p><p class="cs95E872D0"><span class="csDD5E5F52">03/31/2022 &nbsp;&nbsp;1254s</span></p><p class="cs2E86D3A6"><span class="csDD5E5F52">2022 SESSION</span></p><p class="cs95E872D0" style="tab-stops:left 396pt;"><span class="csDD5E5F52">\t22-3071</span></p><p class="cs95E872D0" style="tab-stops:left 396pt;"><span class="csDD5E5F52">\t05/11</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs95E872D0" style="tab-stops:left 108pt;"><span class="csDD5E5F52">SENATE BILL\t</span><span class="csED7826F6">450</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="csE0B838BE"><span class="csDD5E5F52">AN ACT\t</span><a name="bkTitleDraft0"><span class="csDD5E5F52">relative to the prescription drug affordability board.</span></a></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="csE0B838BE" style="tab-stops:left 86.45pt;"><span class="csDD5E5F52">SPONSORS:\tSen. Sherman, Dist 24; Sen. Rosenwald, Dist 13; Sen. Watters, Dist 4; Sen. Carson, Dist 14; Sen. Gannon, Dist 23; Sen. Perkins Kwoka, Dist 21; Sen. Prentiss, Dist 5; Rep. Merchant, Sull. 4; Rep. Marsh, Carr. 8; Rep. Murphy, Graf. 12</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="csE0B838BE" style="tab-stops:left 86.45pt;"><span class="csDD5E5F52">COMMITTEE:\tHealth and Human Services</span></p><p class="cs95E872D0" style="tab-stops:left 90pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs95E872D0" style="tab-stops:left 90pt;"><span class="csA16174BA">-----------------------------------------------------------------</span></p><p class="cs95E872D0" style="tab-stops:left 90pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs2E86D3A6"><span class="csDD5E5F52">AMENDED ANALYSIS</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs9224F58F" style="tab-stops:left 18pt left 86.45pt;"><span class="csDD5E5F52">\tThis bill clarifies the definition of manufacturer and pricing unit for purposes of the prescription drug affordability board; expands the ability of alternates to sit on the prescription drug affordability board; changes the executive director position from a classified to unclassified position; clarifies the board&#39;s authority to assess fees; establishes a dedicated fund to support the board; and establishes a criminal penalty for violation of confidentiality requirements.</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs95E872D0"><span class="csDD5E5F52">- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - </span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="csC970676" style="tab-stops:left 14.4pt left 82.8pt;"><span class="cs5ADD8C59">Explanation:\tMatter added to current law appears in </span><span class="csE2DB38B2">bold italics.</span></p><p class="csC970676" style="tab-stops:left 14.4pt left 82.8pt;"><span class="cs5ADD8C59">\t\tMatter removed from current law appears [</span><span class="cs5D3E032C">in brackets and struckthrough.</span><span class="cs5ADD8C59">]</span></p><p class="csC970676" style="tab-stops:left 14.4pt left 82.8pt;"><span class="cs5ADD8C59">\t\tMatter which is either (a) all new or (b) repealed and reenacted appears in regular type.</span></p><p class="csC970676" style="tab-stops:left 396pt;"><span class="csDD5E5F52">03/31/2022 &nbsp;&nbsp;1202s</span></p><p class="csC970676" style="tab-stops:left 396pt;"><span class="csDD5E5F52">03/31/2022 &nbsp;&nbsp;1254s\t22-3071</span></p><p class="csC970676" style="tab-stops:left 396pt;"><span class="csDD5E5F52">\t05/11</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs41ED3027" style="tab-stops:left 396pt;"><span class="csDD5E5F52">STATE OF NEW HAMPSHIRE</span></p><p class="cs41ED3027" style="tab-stops:left 396pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs41ED3027" style="tab-stops:left 396pt;"><span class="csE3E0FE0B">In the Year of Our Lord Two Thousand Twenty Two</span></p><p class="csC970676" style="tab-stops:left 396pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="csE0B838BE"><span class="csDD5E5F52">AN ACT\t</span><a name="bkTitleDraft1"><span class="csDD5E5F52">relative to the prescription drug affordability board.</span></a></p><p class="cs5CA3ADAD" style="tab-stops:left 396pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs41ED3027" style="tab-stops:left 396pt;"><span class="csE3E0FE0B">Be it Enacted by the Senate and House of Representatives in General Court convened:</span></p><p class="csD15247B9"><span class="csDD5E5F52">&nbsp;</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt1"></a><span class="csDD5E5F52">1 &nbsp;New Hampshire Prescription Drug Affordability Board; Definition of Manufacturer and Pricing Unit. &nbsp;Amend RSA 126-BB:1, IV and V to read as follows:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tIV. &nbsp;&quot;Manufacturer&quot; means a manufacturer of prescription drugs that are distributed in the state. &nbsp;A manufacturer excludes a packager, repackager, labeler, and relabeler</span><span class="cs22FF6315"> unless the packager, repackager, labeler, or relabeler sets the price or controls the price of a prescription drug</span><span class="csDD5E5F52">. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tV. &nbsp;&quot;Pricing unit&quot; means the smallest [</span><span class="cs98AF35F2">dispensable amount of a prescription drug that could be dispensed</span><span class="csDD5E5F52">] </span><span class="cs22FF6315">available package that can be used to dispense the smallest amount of a prescription drug</span><span class="csDD5E5F52">. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt2"></a><span class="csDD5E5F52">2 &nbsp;New Hampshire Prescription Drug Affordability Board; Alternates. &nbsp;Amend RSA 126-BB:2, I to read as follows:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tI. &nbsp;The board shall consist of 5 members with expertise in health care economics or clinical medicine, who shall not be, or be directly related to, anyone affiliated with, employed by, or representing the interests of a public payor, pharmaceutical or pharmacy company, pharmacy benefits management company, or health insurance provider and who have completed a conflict of interest statement. &nbsp;</span><span class="cs22FF6315">A member may be a legislator but is not required to be a legislator. &nbsp;</span><span class="csDD5E5F52">They shall be appointed as follows: </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(a) &nbsp;Two members by the president of the senate. &nbsp;The president of the senate shall also appoint [</span><span class="cs98AF35F2">one</span><span class="csDD5E5F52">] </span><span class="cs22FF6315">2 </span><span class="csDD5E5F52">alternate board [</span><span class="cs98AF35F2">member</span><span class="csDD5E5F52">] </span><span class="cs22FF6315">members </span><span class="csDD5E5F52">who will participate in deliberations of the board in the event a member appointed by the president of the senate elects to be recused as provided in RSA 126-BB:3 </span><span class="cs22FF6315">or is absent</span><span class="csDD5E5F52">. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(b) &nbsp;Two members by the speaker of the house of representatives. &nbsp;The speaker of the house of representatives shall also appoint [</span><span class="cs98AF35F2">one</span><span class="csDD5E5F52">] </span><span class="cs22FF6315">2 </span><span class="csDD5E5F52">alternate board [</span><span class="cs98AF35F2">member</span><span class="csDD5E5F52">] </span><span class="cs22FF6315">members </span><span class="csDD5E5F52">who will participate in deliberations of the board in the event a member appointed by the speaker of the house of representatives elects to be recused as provided in RSA 126-BB:3</span><span class="cs22FF6315"> or is absent</span><span class="csDD5E5F52">. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(c) &nbsp;One member by the governor. &nbsp;The governor shall also appoint [</span><span class="cs98AF35F2">one</span><span class="csDD5E5F52">] </span><span class="cs22FF6315">2 </span><span class="csDD5E5F52">alternate board [</span><span class="cs98AF35F2">member</span><span class="csDD5E5F52">] </span><span class="cs22FF6315">members </span><span class="csDD5E5F52">who shall participate in deliberations of the board in the event the member appointed by the governor elects to be recused as provided in RSA 126-BB:3</span><span class="cs22FF6315"> or is absent</span><span class="csDD5E5F52">. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt3"></a><span class="csDD5E5F52">3 &nbsp;New Hampshire Prescription Drug Affordability Board; Executive Director. &nbsp;Amend RSA 126-BB:2, VI to read as follows:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tVI. &nbsp;The board shall be administratively attached to the department of health and human services. &nbsp;The board may employ </span><span class="cs22FF6315">staff, including but not limited to,</span><span class="csDD5E5F52"> an executive director who shall be [</span><span class="cs98AF35F2">a classified</span><span class="csDD5E5F52">] </span><span class="cs22FF6315">an unclassified </span><span class="csDD5E5F52">employee. &nbsp;</span><span class="cs22FF6315">The executive director shall be appointed by and serve at the pleasure of the board</span><span class="csDD5E5F52">. &nbsp;</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt4"></a><span class="csDD5E5F52">4 &nbsp;Salary; Executive Director of the New Hampshire Prescription Drug Affordability Board. &nbsp;The salary for the executive director of the New Hampshire prescription drug affordability board shall be determined after assessment and review of the appropriate temporary letter grade allocation in RSA 94:1-a, I(b) for the position which shall be conducted pursuant to RSA 94:1-d and RSA 14:14-c.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt5"></a><span class="csDD5E5F52">5 &nbsp;New Subparagraph; New Hampshire Prescription Drug Affordability Board; Conflicts of Interest. &nbsp;Amend RSA 126-BB:3, II by inserting after subparagraph (f) the following new subparagraph:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="cs22FF6315">\t\t\t</span><span class="csDD5E5F52">(g) &nbsp;Notwithstanding the prohibition in RSA 21-G:25, I, any person whose employer cannot and will not directly benefit from action taken or not taken by the board may be appointed to, and serve as a member of, the board.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt6"></a><span class="csDD5E5F52">6 &nbsp;Funding; Assessment of Fees. &nbsp;Amend RSA 126-BB:8, I(e) to read as follows:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(e) &nbsp;Annual assessments of not less than $500 assessed by the board against prescription drug manufacturers, wholesale drug distributors, and pharmacy benefits managers</span><span class="cs22FF6315">, including those that process and pay claims on the basis of claims processed or paid for each plan sponsor</span><span class="csDD5E5F52">. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt7"></a><span class="csDD5E5F52">7 &nbsp;New Hampshire Prescription Drug Affordability Board; Assessments. &nbsp;Amend RSA 126-BB:8, II to read as follows:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tII. &nbsp;The aggregate level of annual assessments under subparagraphs (c) and (e) shall be an amount sufficient to meet the board&#39;s expenditures authorized</span><span class="cs22FF6315">; provided that such amount shall not exceed 125 percent of the board&#39;s annual operating costs</span><span class="csDD5E5F52">. &nbsp;The board may waive assessments otherwise due under subparagraphs (c) and (e) when a waiver is determined to be in the interests of the board and the parties to be assessed. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="cs22FF6315">\t\tII-a. &nbsp;Any entity assessed a fee or other assessment under this section may appeal such action in accordance with RSA 541.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt8"></a><span class="csDD5E5F52">8 &nbsp;New Hampshire Prescription Drug Affordability Board; Rulemaking; Appeal. &nbsp;Amend RSA 126-BB:6, IV to read as follows:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tIV. &nbsp;</span><span class="cs22FF6315">The appeals process for assessments issued by the board under RSA 126-BB:8. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="cs22FF6315">\t\tV. &nbsp;</span><span class="csDD5E5F52">Any other matter required to implement this chapter. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt9"></a><span class="csDD5E5F52">9 &nbsp;New Paragraph; New Hampshire Prescription Drug Affordability Board; Dedicated Fund. &nbsp;Amend RSA 126-BB:8 by inserting after paragraph II the following new paragraph:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tIII. &nbsp;There is established a nonlapsing fund to be known as the New Hampshire prescription drug affordability board administration fund, which shall be kept distinct and separate from all other funds. &nbsp;The fund shall be continually appropriated to and administered by the board. &nbsp;All fees and assessments collected under this section shall be deposited in the fund. &nbsp;The board shall use the fund, consistent with the provisions of this chapter, to receive funds and to reimburse costs incurred by the board. &nbsp;The fund may be used to pay administrative, technical, legal support, or other costs incurred by the board under this chapter. &nbsp;The state treasurer may invest moneys in the fund as provided by law, and all interest received on such investment shall be credited to the fund. &nbsp;</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt10"></a><span class="csDD5E5F52">10 &nbsp;New Section; Criminal Penalty. &nbsp;Amend RSA 126-BB by inserting after section 9 the following new section:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t126-BB:9-a &nbsp;Criminal Penalty. &nbsp;Any person who knowingly uses confidential information obtained pursuant to this chapter or knowingly discloses confidential information obtained pursuant to this chapter to any person not authorized to review such information shall be guilty of a misdemeanor.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt11"></a><span class="csDD5E5F52">11 &nbsp;New Subparagraph; Dedicated Fund. &nbsp;Amend RSA 6:12, I(b) by inserting after subparagraph (382) the following new subparagraph:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(383) &nbsp;Moneys deposited in the New Hampshire prescription drug affordability board administration fund, established in RSA 126-BB:8, III.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt12"></a><span class="csDD5E5F52">12 &nbsp;Repeal. &nbsp;RSA 126-BB:8, I(c)(4), relative to annual assessment of pharmacy benefits managers, is repealed.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt13"></a><span class="csDD5E5F52">13 &nbsp;Effective Date. &nbsp;This act shall take effect July 1, 2022.</span></p>'